[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-ischemic-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-ischemic-stroke":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,238,0,25,[9,42,71,98,122,146,168,198,218,237,265,289,317,335,361,384,404,425,449,472,501,523,557,582,613],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100620721","phase-3-a-study-to-test-if-tenecteplase-helps-people-to-recover-from-an-acute-stroke-when-given-more-than-45-hours-after-the-person-was-last-seen-well-100620721",false,"NCT07361302","A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well","TENACITY - A Phase III, Prospective, Randomized, Open-label, Blinded Endpoint Assessment (PROBE) to Assess Efficacy and Safety of i.v. Tenecteplase vs Standard of Care in Patients With Acute Ischemic Stroke (Including Wake-up Stroke), Last Known Well >4.5 h With Imaging Evidence of Salvageable Ischemic Tissue","TENACITY","Inclusion criteria:\n\n1. Male or female ≥18 years old and at least at the legal age of consent in countries where it is greater than 18 years\n2. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial\n3. Acute ischaemic stroke (including wake-up stroke) affecting the supratentorial circulation (anterior cerebral artery (ACA), middle cerebral artery (MCA), and posterior cerebral arteries (PCA)) last known well \\>4.5 h before time of presumed randomisation\n4. Pre-stroke modified Rankin scale (mRS) ≤1\n5. Imaging eligibility by magnetic resonance imaging (MRI)computed tomography (CT)\n\nExclusion criteria:\n\n1. Intention to proceed to mechanical thrombectomy (MT) at the same site (hospital) of randomisation\n2. Occlusion of the internal carotid artery (ICA)\n3. High-risk patients (increased risk of thrombolysis related hemorrhage)\n4. Any intracranial hemorrhage detected on non-contrast computed tomography (NCCT) or MRI scans\n5. Contra-indication to contrast brain imaging with CT and MRI\n6. Severe stroke as assessed clinically (National Institute of Health Stroke Scale (NIHSS) \\> 25)\n7. Non-disabling minor stroke symptoms (NIHSS ≤5), or rapidly improving symptoms at the discretion of the investigator\n8. Imaging or clinical findings not indicative of acute ischemic stroke or suggesting stroke older than 72 h\n9. Patients scheduled to receive intravenous (i.v.) thrombolysis as standard of care Further exclusion criteria apply.","ALL","18 Years",{"count":21,"type":22},1325,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke). This study is for people who had an acute stroke or woke up with a stroke and were last seen well more than 4.5 hours before joining the study. Participants need to have imaging that shows there is brain tissue that can still be saved. They also should not be planned to receive a procedure to remove the blood clot.\n\nThe purpose of this study is to find out whether a medicine called tenecteplase helps people recover from an acute stroke. Tenecteplase is already used to treat people within 4.5 hours after they had a stroke. This study tests if tenecteplase also helps if it is given more than 4.5 hours after the stroke.\n\nParticipants are put into 2 groups randomly, which means by chance. One group gets tenecteplase as a single injection into a vein. The other group receives standard medical practice. Participants have an equal chance of receiving tenecteplase or the standard treatment.\n\nParticipants are in the study for about 3 months. In the beginning, participants stay in the hospital for about 1 week. During the study, participants have 7 clinical examinations or visits. The last 2 of these visits will likely be done from home, allowing participants to complete certain assessments remotely. Doctors regularly test participants' recovery using a scale that measures the level of disability or dependence in daily activities. The results are compared between the 2 groups to see whether the treatment works. The doctors also check participants' health and take note of any unwanted effects.",[28],"Acute Ischemic Stroke","RECRUITING","2026-08-19",{"date":32,"type":33},"2026-08-20","ACTUAL",{"date":35,"type":33},"2026-02-17",{"date":37,"type":22},"2027-10-02",{"name":39,"class":40},"Boehringer Ingelheim","INDUSTRY",250,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100612407","phase-3-tenecteplase-before-interhospital-transfer-for-evt-in-acute-anterior-circulation-lvo-at-45-24-hours-100612407","NCT07253181","Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours","Tenecteplase Before inteRhospital Transfer for Endovascular Treatment in pAtientS With acUte Anterior ciRculation Large vEssel Occlusion at 4.5 to 24 Hours","TREASURE","Inclusion Criteria:\n\n* Age of 18 years or older;\n* AIS symptom onset to treatment initiation within 4.5 to 24 hours, stroke onset is defined as the time the patient was last known to be well (including wake-up stroke and unwitnessed stroke);\n* Signs and symptoms consistent with the diagnosis of an acute anterior circulation ischemic stroke involving occlusion of the internal carotid artery (ICA), M1 or proximal M2 vessels;\n* Functionally independent (mRS 0-2) prior to stroke onset;\n* Baseline National Institute of Health Stroke Scale (NIHSS) of 6-25;\n* Intended to transfer to ECCs for EVT (patient transfer), or intended to transfer a neurointerventionalist from the ECC for EVT (physician transfer);\n* Written informed consent from patients or legally authorized representatives;\n* Neuroimaging: large vessel occlusion (ICA, M1, proximal M2) by MRA or CTA AND the target mismatch profile on computed tomography perfusion (CTP) or magnetic resonance perfusion (MRP), defined as an ischemic core volume \\\u003C70mL, mismatch volume ≥15mL and mismatch ratio ≥1.8;\n\nAlternative neuroimaging (if CTP or MRP is technically inadequate or unavailable):\n\nAn Alberta Stroke Program Early CT Score (ASPECTS) score ≥7 on NCCT or MRI scan;\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to any ingredients of Tenecteplase;\n* Intended to receive IVT as standard-of-care therapy;\n* Rapidly improving symptoms with NIHSS score \\\u003C6 before randomization;\n* Any contra-indication for IVT except for the time criterion;\n* Known hereditary or acquired hemorrhagic diathesis;\n* Impairment in coagulation due to comorbid disease or anticoagulant use. If on warfarin, INR \\>1.7 or prothrombin time \\>15s; if use of any direct oral anticoagulant within the last 48 hours; if on any full dose heparin\u002Fheparinoid within the last 24 hours;\n* Ischemic stroke or myocardial infarction in previous 3 months\n* Previous intracranial hemorrhage, active internal bleeding (gastrointestinal or urinary tract hemorrhage) in previous 3 months;\n* Severe, uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg);\n* Other serious, advanced or terminal illness with life expectancy less than 6 months;\n* Baseline blood glucose \\\u003C50mg\u002Fdl or \\>400mg\u002Fdl;\n* Contraindication to imaging with contrast agents;\n* Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA or MRA (e.g. bilateral MCA occlusions, or an MCA and a basilar artery occlusion);\n* Extensive early ischemic change on non-contrast CT or MRI-DWI estimated to be \\>1\u002F3 MCA territory, or significant hypodensity outside the Tmax\\>6s perfusion lesion that invalidates mismatch criteria (if patient is enrolled based on CT perfusion criteria); any CT or MRI findings indicative of a high risk of sICH related to potential intravenous tenecteplase treatment in the judgement of the investigator;\n* Evidence of intracranial tumor (mass effect), acute intracranial hemorrhage, or arteriovenous malformation;\n* Current participation in another investigational drug or device study;\n* Suspected endocarditis;\n* Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;",{"count":51,"type":22},572,[25],"This study will address the efficacy and safety of Tenecteplase administered in non-endovascular capable center (nECC) in patients with acute ischemic stroke (AIS) caused by anterior circulation large vessel occlusion (acLVO) who present in the 4.5- to 24-hour time window before interhospital transfer to an endovascular capable center (ECC) for endovascular treatment (EVT).\n\n* Primary objective: To evaluate the efficacy and safety of Tenecteplase administration at a nECC before EVT transfer compared with standard of care\n* Secondary objective: To evaluate the impact of time from needle-to-arterial puncture on clinical outcomes Patients who meet inclusion criteria will be randomized to Tenecteplase (0.25mg\u002Fkg, maximum 25mg) before transfer or standard of care. A single bolus dose should be injected over 5 seconds.",[28,55,56],"Large Vessel Occlusion","Transportation of Patients",[58,59,60],"interhospital transfer","acute ischemic stroke","anterior circulation large vessel occlusion","2026-08-18",{"date":30,"type":33},{"date":64,"type":33},"2026-01-06",{"date":66,"type":22},"2028-03-30",{"name":68,"class":69},"Xuanwu Hospital, Beijing","OTHER",2,{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100652588","phase-3-intravenous-recombinant-human-prourokinase-for-acute-medium-vessel-occlusion-45-24-hours-after-ischemic-stroke-100652588","NCT07776873","Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke","Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke - A Multicenter, Prospective, Randomized, Open-label, Blinded Endpoint Trial（HOPE-MeVO）","HOPE-MeVO","Inclusion Criteria:\n\n* Age ≥18 years.\n* Pre-stroke modified Rankin Scale (mRS) score of 0-1.\n* Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥6, or an NIHSS score of 4-5 with a disabling neurological deficit, including but not limited to hemianopia, aphasia, or impaired hand motor function.\n* Time from last known well of 4.5 to 24 hours, including wake-up stroke or unwitnessed stroke. Symptom onset is defined as the last time the participant was known to be well.\n* Primary medium vessel occlusion confirmed by computed tomography angiography (CTA), involving the M2, M3, or M4 segment of the middle cerebral artery (MCA); the A1, A2, A3, or A4 segment of the anterior cerebral artery (ACA); or the P1, P2, P3, or P4 segment of the posterior cerebral artery (PCA), and identified as the responsible vessel for the signs and symptoms of acute ischemic stroke.\n* Perfusion mismatch on computed tomography perfusion (CTP), defined as an infarct core volume \\\u003C50 mL, a hypoperfused volume\u002Finfarct core volume ratio ≥1.2, and a hypoperfused volume minus infarct core volume ≥10 mL. The infarct core is defined as tissue with relative cerebral blood flow (rCBF) \\\u003C30%, and the hypoperfused region as tissue with Tmax \\>6 seconds.\n* Written informed consent provided by the participant or the participant's legally authorized representative.\n\nExclusion Criteria:\n\n* Planned direct endovascular treatment (EVT).\n* Known history of severe hypersensitivity to recombinant human prourokinase, human albumin, mannitol, iodinated contrast media, or medications used for study-related examinations or treatment.\n* Rapidly improving clinical symptoms such that, in the investigator's judgment, the participant is not suitable for the study intervention.\n* Seizure at stroke onset when, in the investigator's judgment, the neurological deficit may be attributable to postictal Todd paralysis or another non-ischemic cause.\n* Other severe neurological, psychiatric, or systemic disease that may substantially affect efficacy assessment, compliance, or completion of follow-up.\n* Persistent severe hypertension that cannot be adequately controlled with medication, defined as systolic blood pressure ≥185 mmHg or diastolic blood pressure ≥110 mmHg before treatment and remaining uncontrolled after antihypertensive treatment.\n* Blood glucose \\\u003C2.8 mmol\u002FL or \\>22.2 mmol\u002FL and, after appropriate treatment, the participant remains unsuitable for enrollment.\n* Active internal bleeding or a condition associated with a high risk of bleeding, including but not limited to gastrointestinal or urinary tract bleeding within the previous 21 days; major surgery, severe trauma, or biopsy of a major organ within the previous 21 days; arterial puncture at a noncompressible site within the previous 7 days; or any other condition considered by the investigator to confer a substantial bleeding risk.\n* Known coagulation abnormality or bleeding tendency, including but not limited to platelet count \\\u003C100 × 10\\^9\u002FL, international normalized ratio (INR) \\>1.7, markedly prolonged prothrombin time (PT), activated partial thromboplastin time (APTT) above the upper limit of normal and considered clinically significant, or markedly reduced fibrinogen level.\n* Current or recent use of anticoagulant therapy associated with an increased thrombolysis-related bleeding risk, including use of a vitamin K antagonist with INR \\>1.7; use of a direct thrombin inhibitor or factor Xa inhibitor within the previous 48 hours with abnormal relevant coagulation tests; or use of heparin within the previous 24 hours with APTT above the upper limit of normal.\n* History of ischemic stroke, severe head trauma, or myocardial infarction within the previous 3 months.\n* History of intracranial hemorrhage.\n* Intracranial or intraspinal surgery within the previous 3 months.\n* Known intracranial tumor, cerebral arteriovenous malformation, giant intracranial aneurysm, or other intracranial lesion that may substantially increase the risk of intracranial hemorrhage.\n* Baseline head CT showing acute or previous intracranial hemorrhage, including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma, or epidural hematoma.\n* Baseline imaging showing a large cerebral infarction or marked early ischemic changes such that, in the investigator's judgment, intravenous thrombolytic treatment is inappropriate.\n* Known severe adverse reaction to contrast media.\n* Unable to undergo the required head CT, CTA, or CTP examinations, or imaging quality is insufficient to determine the responsible vessel occlusion and perfusion mismatch.\n* Severe renal impairment with estimated glomerular filtration rate \\\u003C30 mL\u002Fmin or serum creatinine \\>2.5 mg\u002FdL.\n* Currently receiving hemodialysis or peritoneal dialysis.\n* Suspected aortic dissection.\n* Any advanced terminal illness with an anticipated life expectancy of no more than 6 months.\n* Pregnant or breastfeeding women, or women of childbearing potential with a positive pregnancy test.\n* Inability, in the investigator's judgment, to complete the 90-day follow-up, poor expected compliance, or otherwise unsuitable for participation in the study.\n* Current participation in another interventional clinical study that may affect the efficacy or safety evaluation of this study, or participation in another interventional clinical study within the previous 3 months.",{"count":80,"type":22},616,[25],"The HOPE-MeVO study aims to evaluate the efficacy and safety of intravenous recombinant human prourokinase (rhPro-UK) in patients with acute ischemic stroke due to medium vessel occlusion presenting 4.5 to 24 hours after stroke onset or last known well. Eligible patients will be selected based on CT perfusion imaging and randomly assigned to receive rhPro-UK plus standard medical treatment or standard medical treatment alone. The primary objective is to determine whether rhPro-UK improves functional outcome at 90 days.",[28],[85,86,87],"Medium Vessel Occlusion","Recombinant Human Prourokinase","Late-Window Intravenous Thrombolysis","NOT_YET_RECRUITING","2026-08-17",{"date":32,"type":33},{"date":92,"type":22},"2026-09-06",{"date":94,"type":22},"2029-06-30",{"name":96,"class":69},"The First Affiliated Hospital of Anhui Medical University",1,{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100650381","ultra-early-identification-of-futile-recanalization-after-reperfusion-therapy-in-acute-ischemic-stroke-based-on-cerebral-autoregulation-monitoring-100650381","NCT07747701","Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation Monitoring","Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation Monitoring: a Multicenter, Prospective, Interventional Study","FACTOR","Inclusion Criteria:\n\n1. Age ≥ 18\n2. Diagnosis of acute ischemic stroke caused by anterior circulation large vessel occlusion (intracranial internal carotid artery or M1 segment of the middle cerebral artery).\n3. National Institutes of Health Stroke Scale (NIHSS) score ≥ 6 at presentation.\n4. Pre-stroke modified Rankin Scale (mRS) score ≤ 1.\n5. Symptom onset ≤ 24 hours.\n6. For patients with symptom onset within 6 hours: ASPECTS ≥ 6; for patients with symptom onset between 6 and 24 hours: age ≤ 80 years and ASPECTS ≥ 3.\n7. Underwent mechanical thrombectomy and achieved successful recanalization (mTICI 2b-3).\n8. Patient or legally authorized representative provides written informed consent.\n\nExclusion Criteria:\n\n1. Pre-procedural baseline imaging showing significant intracranial hemorrhagic transformation, intracranial arterial dissection, large chronic cerebral infarction, or intracranial metastasis from malignant tumors.\n2. Any degree of stenosis, plaque, dissection, severe tortuosity, or imaging evidence of unstable\u002Fvulnerable plaque in the target-side or bilateral common carotid artery or the origin of the internal carotid artery.\n3. Known history of carotid sinus hypersensitivity syndrome, severe autonomic dysfunction, sick sinus syndrome, high-grade atrioventricular conduction block, or other malignant arrhythmias.\n4. Refractory malignant hypertensive crisis (systolic blood pressure persistently ≥ 200 mmHg despite standardized intravenous antihypertensive therapy, or hemodynamic instability with shock).\n5. Known severe allergy to contrast agents or anesthetic drugs, or contraindications to antiplatelet\u002Fanticoagulation therapy.\n6. Severe systemic active infection, multiple organ failure, or expected survival \\\u003C 6 months.\n7. Severe hepatic or renal dysfunction (ALT\u002FAST \\> 3× upper limit of normal; estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin) or severe coagulation disorders (platelet count \\\u003C 40 × 10⁹\u002FL, APTT \\> 50 s, INR \\> 3.0).\n8. Blood glucose \\\u003C 2.7 mmol\u002FL or \\> 22.2 mmol\u002FL.\n9. Heart failure with NYHA class \\> II, or persistent systolic blood pressure \\\u003C 100 mmHg.\n10. Central nervous system infection or intracranial tumor.\n11. Unstable vital signs.\n12. Severe alcohol dependence or drug dependence.\n13. Cognitive impairment or psychiatric disorders that may affect follow-up assessments.\n14. Pregnant or breastfeeding women.\n15. Participation in another clinical drug or device study within the past 30 days.\n16. Local skin damage or other conditions preventing proper placement of monitoring electrodes.\n17. Severe agitation or other conditions that interfere with data acquisition.\n18. Any other condition judged by investigators to potentially affect study results.",{"count":107,"type":22},227,[109],"NA","This multicenter, prospective, and interventional diagnostic accuracy study enrolls patients undergoing thrombectomy with intraoperative cerebral autoregulation monitoring and follows them up at predefined time points up to 90 days post-enrollment.This study aims to evaluate a monitoring system based on cerebral autoregulation function and explore its predictive value for adverse neurological outcomes at the ultra-early stage following mechanical thrombectomy.",[28,112],"Cerebral Autoregulation","2026-08-14",{"date":89,"type":33},{"date":116,"type":22},"2026-07-31",{"date":118,"type":22},"2027-02-05",{"name":120,"class":69},"Beijing Shijitan Hospital, Capital Medical University",4,{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},"100623116","phase-2-a-study-of-tak-755-in-adults-with-acute-ischemic-stroke-100623116","NCT07392450","A Study of TAK-755 in Adults With Acute Ischemic Stroke","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke","Inclusion Criteria:\n\nInformed Consent:\n\n1. The participant or legally authorized representative has provided informed consent or deferred consent eligibility confirmed before the initiation of any trial procedures.\n\n   Age:\n2. greater than and equal to (\\>=) 18 years of age, inclusive, at the time of signing the Informed Consent Form (ICF) or confirmation of deferred consent eligibility.\n\n   Clinical Characteristics:\n3. Clinical diagnosis of AIS.\n4. Onset of stroke symptoms within 24 hours of randomization. Wake-up strokes may be included if Last Known Well is within 24 hours of randomization; time of onset will be considered the time of Last Known Well.\n5. National Institutes of Health Stroke Scale score of 5 to 25, indicating moderate to severe stroke. Participants with an NIHSS score of 5 are eligible only if at least 1 predefined disabling neurological deficit is present, as defined by one or more of the following\n\n   NIHSS criteria:\n   * Complete hemianopia (NIHSS visual score \\>=2).\n   * Aphasia impairing meaningful communication (NIHSS language score \\>=2).\n   * Motor deficit with inability to sustain effort against gravity (NIHSS left or right motor arm or leg score \\>=2).\n6. Estimated Modified Rankin Scale score less than (\\\u003C) 2 prior to AIS presentation, signifying no significant disability.\n7. Persistent neurological signs and symptoms consistent with unilateral supratentorial circulation stroke.\n\n   Imaging:\n8. Evidence of causative AIS occlusions affecting supratentorial circulation on imaging (intracranial internal carotid artery \\[ICA\\], middle cerebral artery \\[MCA; M1 - M4\\], anterior cerebral artery \\[ACA; A1 - A3\\], posterior cerebral artery \\[PCA; P1 - P3\\]).\n9. Evidence of salvageable brain tissue on CT or MR imaging.\n\nExclusion Criteria:\n\nMedical History:\n\n1. Weight \\>130 kilograms (kg) or \\\u003C40 kg.\n2. History of severe traumatic brain injury in the past 90 days.\n3. History of intracranial hemorrhage.\n4. History of intracranial neoplasm except for small meningioma.\n5. History of prior stroke in the past 90 days.\n6. History of intracranial or intraspinal surgery within the past 90 days.\n7. Major surgery or severe trauma in the past 14 days.\n8. History of cerebral amyloid angiopathy.\n9. Recent history of active systemic malignancy within the last 5 years, except for locally excised basal cell or squamous cell skin carcinoma with clear margins.\n10. Diagnosis of serious, advanced, or terminal illness with anticipated life expectancy of less than 1 year.\n11. Participation in other interventional clinical trials within the previous 90 days.\n12. Known life-threatening hypersensitivity reaction to TAK-755 or its components.\n13. Any prior administration of TAK-755.\n14. Administration of caplacizumab in the past 30 days.\n15. Administration of von Willebrand factor-containing products in the past 14 days.\n16. Baseline conditions (prior to the index AIS event) that prevent an understanding of the nature, scope, and possible consequences of the trial, in the judgment of the investigator.\n\n    Current Stroke Management:\n17. Any prior administration (intravenous or intra-arterial) of alteplase or tenecteplase for the index AIS event, as well as any prior administration of prourokinase or reteplase for the index AIS event in countries where approved.\n18. Eligible for administration of intravenous thrombolysis (alteplase or tenecteplase, as well as prourokinase or reteplase in countries where approved) for the index AIS event, based on the site's standard clinical guidelines and direct availability.\n19. Intent to proceed with endovascular thrombectomy (EVT) for the index AIS event based on eligibility and direct availability.\n20. Seizure at time of index AIS event onset, only if it precludes accurate assessment of baseline NIHSS.\n21. Persistent blood pressure elevation (systolic \\>=185 millimeters of mercury \\[mmHg\\] or diastolic \\>=110 mm Hg) prior to randomization.\n22. Blood glucose \\\u003C50 milligrams per deciliter (mg\u002FdL) or \\>400 mg\u002FdL.\n\n    Current Medical Conditions:\n23. Active, uncontrolled bleeding.\n24. Bleeding diathesis or any other conditions that would pose significant bleeding risk.\n25. Inability to undergo MRI or CT.\n26. Chronic causative intracranial occlusion.\n27. Causative total occlusion of the extracranial ICA.\n28. Evidence of septic emboli or bacterial endocarditis.\n29. Another clinically significant concomitant disease that may pose additional risks for the participant in the opinion of the investigator.\n30. Pregnancy, lactation, or unable to comply with birth control methods or abstinence as specified in the protocol in the opinion of the investigator.\n\n    Imaging:\n31. Poor quality imaging that precludes interpretation according to trial protocol.\n32. Evidence of significant intracranial mass effect or midline shift.\n33. Evidence of acute occlusion in \\>1 vascular territory (right\u002Fleft MCA, right\u002Fleft ACA, right\u002Fleft PCA); multiple occlusions within the same vascular territory are allowed.\n34. Evidence of acute or chronic intracranial hemorrhage (presence of chronic cerebral microbleeds on magnetic resonance imaging \\[MRI\\]) T2\\*-weighted type sequence (such as gradient recalled echo \\[GRE\\] or susceptibility weighted imaging \\[SWI\\]) is not exclusionary if total \\\u003C10 and not consistent with diagnosis of cerebral amyloid angiopathy).\n35. Evidence of extensive early ischemic change estimated to be greater than one-third of the middle cerebral artery territory or evidence of well-demarcated hypoattenuation on computed tomography (CT), if performed, consistent with established infarction and judged by the investigator to correspond to the clinical symptoms of the index AIS.\n36. Evidence of intracranial tumor (except incidental, small meningioma), cerebral aneurysm, or arteriovenous malformation.\n\n    Laboratory:\n37. Platelet count \\\u003C50,000\u002F cubic millimeters (mm\\^3).\n\n    Other:\n38. Identification by the investigator as being potentially unable or unwilling to cooperate with trial procedures.",{"count":130,"type":22},222,[132],"PHASE2","Acute ischemic stroke (AIS) is a medical emergency that happens because of a sudden stop of blood flow to a part of the brain. This happens when a blood clot forms within the vessel (known as thrombotic occlusion) or a clot originating from somewhere else blocks a blood vessel (known as embolic occlusion). Strokes can cause serious health problems, death, and affect one's quality of life. To reduce long-term damage, it is important to restore blood flow to the brain as soon as possible.\n\nThe main aim of this study is to check how safe TAK-755 is, and how well adults with AIS tolerate it. Other aims are to check how well TAK-755 helps participants to manage their everyday activities and to understand whether it helps reduce the seriousness of their stroke symptoms when compared to placebo. A placebo looks like TAK-755, but does not have any medicine in it, to make sure participants do not know which treatment they are taking.\n\nThe participants will receive TAK-755 or placebo once; afterwards, their health will be monitored for about 3 months (90 days). All participants, regardless of their assignment to either TAK-755 or placebo, will receive the usual treatment for AIS as per the hospital's normal practice.",[28],[136],"Drug therapy","2026-08-13",{"date":113,"type":33},{"date":140,"type":33},"2026-05-17",{"date":142,"type":22},"2027-12-06",{"name":144,"class":40},"Takeda",60,{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":23,"phases":156,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":97},"100621515","phase-1-a-study-of-the-safety-tolerability-and-preliminary-efficacy-of-b2065-in-patients-with-acute-ischemic-stroke-100621515","NCT07371624","A Study of B2065 in Patients With Acute Ischemic Stroke","A Phase I\u002FIIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Allogeneic Adipose-Derived Mesenchymal Stromal Cell Injection (B2065) in Participants With Acute Ischemic Stroke.","Inclusion Criteria\n\n1. Aged 18 to 75 years (inclusive of the boundary values), with no restriction on sex.\n2. Patients with ischemic stroke confirmed by imaging examinations (CT\u002FMRI).\n3. Time from onset of stroke symptoms to administration of the investigational product ≤36 hours; for wake-up stroke, the time of onset is defined as the last-known-well time (the last time the patient was observed to be normal).\n4. NIHSS score at screening is 8 to 20.\n5. The patient or legally authorized representative is willing to participate in this trial and agrees to sign the informed consent form.\n\nExclusion Criteria\n\n1. Patients who have received intravenous thrombolysis and\u002For mechanical thrombectomy prior to dosing.\n2. Modified Rankin Scale (mRS) score ≥2 before stroke onset.\n3. Patients who currently have intracranial hemorrhagic diseases (e.g., intracerebral hemorrhage, epidural hematoma, subarachnoid hemorrhage, etc.), or who have brain tumors, cerebrovascular malformations, multiple sclerosis, a history of severe traumatic brain injury, encephalitis, or other conditions causing stroke-like symptoms.\n4. Patients who are unable to undergo CT and\u002For MRI examinations.\n5. Patients with decreased level of consciousness (NIHSS item 1a score ≥2).\n6. Patients who may have major neurologic or psychiatric disorders that seriously interfere with the participant's compliance with trial assessments.\n7. Body temperature \\>38°C prior to dosing, and the investigator assesses that there is a risk of infection.\n8. Patients with uncontrollable active infection; or patients who have received systemic anti-infective therapy within 7 days prior to dosing and, in the investigator's judgment, may be likely to convert to uncontrollable active infection in the short term.\n9. Patients with current or prior severe diseases of other organ systems, including but not limited to:\n\n   1. Patients with severe heart failure (NYHA Class III or IV) and\u002For severe respiratory failure;\n   2. Patients with renal disease with estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m²;\n   3. Advanced liver disease, such as hepatitis or liver cirrhosis;\n   4. Patients positive for hepatitis B surface antigen (HBsAg) and\u002For hepatitis B e antigen (HBeAg); patients positive for hepatitis B e antibody (HBeAb) and\u002For hepatitis B core antibody (HBcAb) with quantitative HBV-DNA above the upper limit of normal; patients with any of the following test results positive: hepatitis C virus antibody (HCV-Ab), Treponema pallidum antibody (TP-Ab), or human immunodeficiency virus antibody (HIV-Ab);\n   5. Patients with hypertension not controlled after taking therapeutic medications, with systolic blood pressure ≥185 mmHg and\u002For diastolic blood pressure ≥110 mmHg;\n   6. Blood glucose \\\u003C2.8 mmol\u002FL (50 mg\u002FdL) or \\>22.2 mmol\u002FL (400 mg\u002FdL).\n10. Screening laboratory tests meeting any of the following criteria:\n\n    1. Serum alanine aminotransferase (ALT) ≥3× upper limit of normal (ULN);\n    2. Serum aspartate aminotransferase (AST) ≥3× ULN;\n    3. Serum creatinine (Cr) ≥2× ULN;\n    4. Absolute neutrophil count (ANC) \\\u003C1.5×10\\^9\u002FL;\n    5. Platelet count (PLT) \\\u003C100×10\\^9\u002FL;\n    6. Hemoglobin (Hgb) \\\u003C90 g\u002FL;\n    7. International normalized ratio (INR) \\>1.7 or activated partial thromboplastin time (APTT) \\>1.25× ULN.\n11. Patients with malignant tumors or other diseases with an expected survival of less than 2 years.\n12. Patients with other acquired or congenital immunodeficiency diseases, or those currently using immunosuppressants.\n13. Patients who, upon screening inquiry, have alcohol dependence or a history of drug abuse.\n14. Pregnant or breastfeeding women; or those who plan to conceive, donate sperm, or donate oocytes during the trial and\u002For are unwilling to take effective contraception measures.\n15. Patients who participated in any other clinical trial within 1 month prior to screening.\n16. Patients who are allergic to any component of the investigational product.\n17. Patients deemed by the investigator to be unsuitable for participation in this trial.","75 Years",{"count":155,"type":22},54,[157,132],"PHASE1","The goal of this clinical trial is to evaluate the safety of B2065, an allogeneic adipose-derived mesenchymal stromal cell (AD-MSC) injection. It will also assess whether B2065 works to treat acute ischemic stroke. The main questions it aims to answer are:\n\nAt what dose range is the drug safe for participants?\n\nWhich dose shows preliminary efficacy?\n\nResearchers will compare B2065 to a placebo (a look-alike substance that contains no drug) to see if B2065 works to treat acute ischemic stroke.\n\nParticipants will:\n\nReceive a single dose of B2065 during hospitalization\n\nVisit the hospital as scheduled for safety and efficacy assessments",[28],"2026-08-11",{"date":137,"type":33},{"date":163,"type":33},"2025-12-31",{"date":165,"type":22},"2027-12",{"name":167,"class":40},"Tasly Pharmaceutical Group Co., Ltd",{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":180,"conditions":181,"keywords":182,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":4},"100542172","cerebrolysin-after-extended-window-endovascular-thrombectomy-100542172","NCT06339411","Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy","Cerebrolysin After Reperfusion in Extended-Window Endovascular Thrombectomy: A Multicenter Randomized Controlled Trial","CARE-EVT","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Acute anterior-circulation ischemic stroke caused by internal carotid artery or M1 or M2 middle cerebral artery occlusion confirmed by computed tomography angiography.\n* Stroke onset-to-groin-puncture interval greater than 6 hours and no more than 24 hours.\n* Prestroke modified Rankin Scale score of 0 to 2.\n* Baseline National Institutes of Health Stroke Scale score of at least 6 with cortical signs.\n* Alberta Stroke Program Early Computed Tomography Score greater than 3.\n* Computed tomography perfusion target mismatch defined as ischemic core volume less than 70 mL, mismatch ratio at least 1.8, and mismatch volume at least 15 mL.\n* Moderate-to-good collateral circulation, defined as filling of more than 50% of the middle cerebral artery territory on computed tomography angiography.\n* Successful endovascular reperfusion, defined as modified Thrombolysis in Cerebral Infarction grade 2b or 3, confirmed before randomization.\n* Study treatment can be initiated within 36 hours of stroke onset.\n* Written informed consent obtained before randomization from the participant or a legally authorized representative.\n\nExclusion Criteria:\n\n* Life expectancy less than 6 months or a serious medical, neurological, or psychiatric condition likely to interfere with study treatment, follow-up, or outcome assessment.\n* Current pregnancy or breastfeeding.\n* Known iodinated contrast allergy that precludes required endovascular or imaging procedures.\n* Acute or chronic renal failure with creatinine clearance less than 30 mL\u002Fmin.\n* Known hypersensitivity or contraindication to Cerebrolysin.\n* Aspartate aminotransferase or alanine aminotransferase greater than 2 times the upper limit of normal, or total bilirubin greater than 2 mg\u002FdL.\n* Blood glucose less than 50 mg\u002FdL or greater than 400 mg\u002FdL.\n* Platelet count less than 50,000\u002Fmm3 or international normalized ratio greater than 3.\n* Seizure at stroke onset that prevents reliable neurological assessment.\n* Pre-existing intracranial hemorrhage or multiple vascular occlusions on baseline neuroimaging.","80 Years",{"count":178,"type":22},100,[132],"Acute ischemic stroke caused by blockage of a large brain artery can lead to severe disability. Endovascular thrombectomy is a catheter-based procedure used to remove the blood clot and restore blood flow. It can benefit selected patients treated 6 to 24 hours after stroke onset, but some patients remain disabled even when the blocked artery is successfully reopened. Ongoing injury to brain tissue, small blood vessels, and the blood-brain barrier may contribute to this incomplete recovery.\n\nThis multicenter randomized clinical trial will evaluate whether Cerebrolysin, given after successful extended-window endovascular thrombectomy, can reduce brain tissue injury and support recovery. The study will enroll 100 adults aged 18 to 80 years at three stroke centers in Taiwan. Participants will be randomly assigned, after successful reperfusion has been confirmed, to receive either Cerebrolysin 30 mL or a matched normal saline placebo by intravenous infusion once daily for 10 consecutive days. The first infusion will begin within 36 hours of stroke onset. All participants will also receive standard stroke care and rehabilitation.\n\nThe primary outcome is final infarct volume measured by diffusion-weighted magnetic resonance imaging on Day 7 to Day 10. Other outcomes include functional recovery at 3 and 12 months, neurological improvement, symptomatic intracranial hemorrhage, cerebral edema, recurrent stroke, mortality, cognition, language, and mood. The study will also examine blood-brain barrier injury using computed tomography perfusion, dynamic contrast-enhanced magnetic resonance imaging, and serial plasma Claudin-5 measurements.\n\nThis study will determine whether Cerebrolysin shows evidence of reducing postreperfusion brain injury after successful thrombectomy and will help guide the design of a larger trial focused on clinical outcomes.",[28],[183,55,184,185,186,187,188,189],"Endovascular Thrombectomy","Extended Time Window","Cerebrolysin","Blood-Brain Barrier","Claudin-5","Neuroprotection","Computed Tomography Perfusion","2026-08-09",{"date":160,"type":33},{"date":193,"type":22},"2026-09-01",{"date":195,"type":22},"2030-12-31",{"name":197,"class":69},"Chang Gung Memorial Hospital",{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":176,"enrollmentInfo":205,"targetDuration":4,"studyType":23,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":214,"leadSponsor":216,"locationsCount":97},"100650951","a-phase-ii-clinical-study-of-lt3001-for-injection-in-the-treatment-of-acute-ischemic-stroke-100650951","NCT07754825","A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke","A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of LT3001 in Participants With Acute Ischemic Stroke (AIS)","Inclusion Criteria:\n\n1. Clinical diagnosis of acute ischemic stroke that causes evaluable neurological impairment;\n2. 6 points ≤ NIHSS score ≤ 25 points at randomization;\n3. Participants who are able to receive the investigational drug within 24 hours after the onset of stroke;\n4. Female Participants of childbearing potential or male Participants whose sexual partner are women of childbearing potential have no pregnancy plan and voluntarily take effective contraceptive measures during the study period and for 3 months after the last dose;\n5. All participants sign the informed consent form by themselves or their guardians after receiving complete study information.\n\nExclusion Criteria:\n\n1. Participants have received or plan to receive endovascular treatment and\u002For intravenous thrombolytic therapyduring this onset period;\n2. Presence of disturbances of consciousness at screening and NIHSS 1a ≥ 2 points;\n3. Neurological signs have improved rapidly and spontaneously at screening;\n4. Participants who have used or are using protocol-prohibited medications after the onset;\n5. Participants with pre-stroke disability;\n6. Imaging evidence of intracranial hemorrhagic diseases, intraparenchymal brain tumor, arteriovenous malformation, aortic arch dissection, other central nervous system lesions that may increase the risk of hemorrhage, or arterial aneurysm requiring treatment;\n7. Massive infarction on imaging;\n8. Participants who are unable to cooperate due to epileptic seizure at the onset of stroke or other concomitant mental disorders or are unwilling to cooperate;\n9. Participants previously diagnosed with concurrent malignant tumors who are currently undergoing anti-tumor treatment or have an expected survival of less than 3 months；\n10. Systolic blood pressure ≥ 180 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg after active antihypertensive therapy;\n11. Acute hemorrhage tendency;\n12. Blood glucose level \\\u003C 50 mg\u002FdL or \\> 400 mg\u002FdL;\n13. Active visceral hemorrhage;\n14. Lactating or pregnant Participants, or women of childbearing potential with positive pregnancy test results;\n15. International normalized ratio \\> 1.7 or prothrombin time \\> 15 s;\n16. Participants with a history of serious hypersensitivity;\n17. Participants who experienced AIS, ICH, acute myocardial infarction or serious head trauma before screening;\n18. Participants who underwent any major surgery before screening;\n19. Participants with a history of active digestive ulcer before screening;\n20. Participants who experienced hemorrhagic disease before screening;\n21. Participants who underwent arterial puncture at the site not easy for hemostasis by compression before screening;\n22. Presence of active hepatitis, cirrhosis, or severe renal insufficiency;\n23. Participants who have participated in another investigational study and used investigational product before screening;\n24. Other conditions unsuitable for participation in this study determined by the Investigator.",{"count":206,"type":22},300,[132],"This phase II clinical study is designed to evaluate the efficacy and safety of LT3001 in the treatment of acute ischemic stroke",[28],"2026-08-05",{"date":212,"type":33},"2026-08-10",{"date":193,"type":22},{"date":215,"type":22},"2027-12-31",{"name":217,"class":40},"Shanghai Pharmaceuticals Holding Co., Ltd",{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":225,"phases":4,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":97},"100650675","forward-functional-outcomes-in-real-world-treatment-and-revascularization-of-non-dominant-and-distal-m2-occlusions-100650675","NCT07749170","FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions","Inclusion Criteria:\n\n1. Participant age ≥ 18\n2. Participant experiencing acute ischemic stroke due to a confirmed primary M2 occlusion in the vertical segment or post-bifurcation in the non-dominant or co-dominant branch of the horizontal segment\n3. NIHSS ≥5 or NIHSS 3-4 with disabling symptoms\n4. Pre-stroke mRS 0-1\n5. For participants undergoing thrombectomy: Planned first-line treatment with Penumbra System reperfusion catheters\n6. Informed consent obtained per Institutional Review Board\u002FEthics Committee requirements\n\nExclusion Criteria:\n\n1. Any stenosis or occlusion in the ICA origin requiring treatment during the procedure or within the 90-day follow-up period.\n2. Known multiple occlusions\n3. Secondary M2 occlusion\n4. Known or high suspicion of underlying ICAD as the cause of the M2 occlusion\n5. Current hospitalization at time of stroke onset and\u002For any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 90 days\n6. Currently participating in an investigational (drug, device, etc.) clinical trial that will influence the endovascular procedure or acute treatment. Participants in secondary prevention, observational, natural history and\u002For epidemiological studies are eligible.\n7. Other medical, behavioral, or psychological conditions that in the opinion of the Investigator could limit the ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study",{"count":41,"type":22},"OBSERVATIONAL","The objective of this study is to collect safety and effectiveness data on the Penumbra System reperfusion catheters in participants with isolated primary non-dominant and distal M2 occlusions who undergo endovascular mechanical thrombectomy (EVT). Additionally, this study aims to observe characteristics and outcomes of participants treated with medical management (MM) alone and those who receive EVT + MM per current medical practice.",[28,228],"Acute Ischemic Stroke (AIS) Related to a Distal Occlusion",{"date":230,"type":33},"2026-08-06",{"date":232,"type":33},"2026-06-26",{"date":234,"type":22},"2028-09",{"name":236,"class":40},"Penumbra Inc.",{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":225,"phases":4,"briefSummary":246,"conditions":247,"keywords":250,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":4},"100650673","impact-of-presenting-symptoms-on-treatment-time-and-outcomes-in-acute-ischemic-stroke-100650673","NCT07750847","Impact of Presenting Symptoms on Treatment Time and Outcomes in Acute Ischemic Stroke","Impact of Presenting Symptoms in Ischemic Stroke Onset on Time Treatment Window and Clinical Outcome of Acute Ischemic Stroke Patients","Inclusion Criteria:\n\n* Patients aged \\>= 18 years at the time of presentation.\n* Confirmed clinical diagnosis of acute first-ever ischemic stroke supported by objective neuroimaging findings via history case taking and emergency CT or MRI scans.\n* Hospital admission initiated within 48 hours of initial symptom onset.\n* Informed consent provided, signed, and dated by the patient or a legally authorized proxy representative.\n\nExclusion Criteria:\n\n* In-hospital stroke onset.\n* Diagnosis of a Transient Ischemic Attack (TIA) or presenting stroke mimics (e.g., complex migraines, severe hypoglycemia, conversion disorders, status epilepticus).\n* Pre-existing severe functional disability prior to the index stroke event, established as a baseline pre-stroke Modified Rankin Scale (mRS) score \\> 2.\n* Co-morbid advanced or terminal medical or neurological or psychiatric conditions with a documented clinical life expectancy of less than 6 months.\n* Incomplete medical charts, structural data gaps, or formal withdrawal on baseline assessment or on hospital stay assessment before discharge.",{"count":245,"type":22},120,"This observational study aims to understand how the specific symptoms a person experiences at the start of an acute ischemic stroke affect how quickly they receive treatment and how well they recover.\n\nIn stroke care, rapid treatment is critical because delayed intervention can lead to more severe disability or death. Patients who experience \"high urgency\" or classic stroke symptoms, such as sudden paralysis, severe facial drooping, or loss of speech, tend to arrive at the emergency room very quickly because these signs are easily recognized by bystanders. In contrast, patients who experience \"low urgency\" or vague symptoms, such as dizziness, numbness, visual changes, or a new-onset headache, often delay seeking medical care. Because these vague symptoms can mimic other medical conditions, they can lead to delayed diagnosis and longer waiting times for specific stroke treatments.\n\nThe researchers will observe 120 adult patients admitted for a first-ever acute ischemic stroke. Participants will be categorized into two groups based on whether their initial stroke symptoms were highly urgent or vague. The study will track and compare both groups to evaluate:\n\n* The time it takes for patients to arrive at the hospital and receive intervention therapies.\n* The patients' level of physical disability and independence in daily activities.\n* The patients' cognitive function.\n* The total length of the hospital stay, complication rates, and overall survival. Participants will be monitored from the time of their hospital admission through their discharge. To measure long-term recovery and functional outcomes, patients will also complete follow-up assessments at two weeks, one month, two months, and three months after leaving the hospital.",[28,248,249],"Ischemic Stroke","Stroke",[251,252,253,254,255,256,257],"Presenting Symptoms","Time Treatment Window","Clinical Outcome","Onset-to-Door Time","Reperfusion Therapy","High Urgency Symptoms","Door-to-Needle Time",{"date":230,"type":33},{"date":260,"type":22},"2026-09",{"date":262,"type":22},"2027-10",{"name":264,"class":69},"Assiut University",{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":176,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":275,"briefSummary":276,"conditions":277,"keywords":278,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":288},"100632403","phase-1-anisodine-hydrobromide-for-patients-with-acute-ischemic-stroke-undergoing-endovascular-therapy-heal-100632403","NCT07513233","Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL)","Safety and Efficacy of Anisodine Hydrobromide in Patients With Ischemic Stroke Undergoing Endovascular Treatment","HEAL","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Imaging-confirmed anterior-circulation large-vessel occlusion involving the intracranial internal carotid artery, the middle cerebral artery M1 segment, or the proximal M2 segment or a dominant M2 branch. A dominant M2 branch was defined as an M2 branch supplying ≥50% of the middle cerebral artery territory.\n* Eligible for and planned to undergo endovascular treatment (EVT) within 24 hours according to current clinical practice.\n* National Institutes of Health Stroke Scale (NIHSS) score ≥6 at baseline.\n* Alberta Stroke Program Early CT Score (ASPECTS) ≥6 on baseline noncontrast CT.\n* Pre-stroke modified Rankin Scale (mRS) score of 0 to 1.\n* Provision of written informed consent by the participant or the participant's legally authorized representative.\n\nExclusion Criteria:\n\n* Evidence of intracranial hemorrhagic disease on head CT, including hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage.\n* History of congenital or acquired bleeding disorders, coagulation factor deficiency, thrombocytopenic disorders, or other clinically significant hemorrhagic conditions.\n* Vascular anatomy expected to preclude successful endovascular treatment because of excessive tortuosity or other technical reasons.\n* Known allergy to iodinated contrast agents.\n* Pregnant or breastfeeding women, or women planning pregnancy during the study period or within 90 days after enrollment.\n* Known hypersensitivity to anisodine hydrobromide or a history of severe intolerance after prior exposure.\n* Presence of clinical conditions that may be worsened by anticholinergic drugs, including but not limited to angle-closure glaucoma, urinary retention or benign prostatic hyperplasia with dysuria, or paralytic ileus.\n* Severe arrhythmia or hemodynamic instability, including but not limited to tachyarrhythmia requiring cardioversion, recurrent syncope due to arrhythmia, vasopressor-dependent hypotension, or persistent hypotension.\n* Severe psychiatric disorder, dementia, or impaired consciousness that would preclude informed consent or protocol-required follow-up.\n* Malignant tumor or other severe systemic disease with an expected survival of less than 90 days.\n* Participation in another interventional clinical study within 30 days before enrollment, or current participation in another interventional clinical study.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.",{"count":274,"type":22},92,[157],"This study is an investigator-initiated Phase 1b clinical trial employing an open-label, non-randomized, dose-escalation design. The primary objective is to evaluate the safety and tolerability of the investigational intervention and to determine the recommended dose for subsequent clinical studies.",[28],[279,188,249],"Endovascular Treatment",{"date":281,"type":33},"2026-08-07",{"date":283,"type":33},"2026-04-28",{"date":285,"type":22},"2026-11-20",{"name":287,"class":69},"Capital Medical University",10,{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":225,"phases":4,"briefSummary":299,"conditions":300,"keywords":301,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":97},"100651042","inflammatory-markers-and-prognosis-after-cerebral-thrombectomy-in-large-vessel-occlusion-100651042","NCT07754942","Inflammatory Markers and Prognosis After Cerebral Thrombectomy in Large Vessel Occlusion","Local-to-Systemic Inflammatory Biomarker Gradients and 90-Day Functional Outcomes in Patients With Acute Ischemic Stroke Due to Anterior Circulation Large Vessel Occlusion Undergoing Mechanical Thrombectomy: A Prospective Observational Cohort Study","IMPACT-LVO","Inclusion Criteria:\n\n* Age 18 years or older.\n* Acute ischemic stroke caused by anterior circulation large vessel occlusion, confirmed by routine vascular imaging or digital subtraction angiography.\n* Undergoing clinically indicated mechanical thrombectomy according to routine clinical practice.\n* Provision of written informed consent by the participant or legally authorized representative, in accordance with local ethics requirements.\n\nExclusion Criteria:\n\n* Posterior circulation large vessel occlusion.\n* Mechanical thrombectomy not performed.\n* Known active systemic infection, active malignancy, or chronic inflammatory\u002Fautoimmune disease requiring systemic immunosuppressive treatment, when these conditions are expected to substantially affect inflammatory biomarker measurements.\n* Pregnancy or breastfeeding, if required by the local ethics committee.\n* Enrollment in another interventional study that could affect inflammatory biomarker measurements or clinical outcome assessment.\n* Inability to obtain informed consent, where consent from a legally authorized representative is not permitted or cannot be obtained.",{"count":298,"type":22},50,"The goal of this observational study is to describe the local change in interleukin-6 (IL-6) across a blood clot in adults with acute ischemic stroke caused by anterior circulation large vessel occlusion who are undergoing mechanical thrombectomy.\n\nThe main questions it aims to answer are:\n\n* Is the level of IL-6 different in arterial blood collected beyond the clot compared with arterial blood collected before the clot during mechanical thrombectomy?\n* Is the trans-thrombus IL-6 difference associated with functional independence 90 days after stroke and with complications related to reperfusion injury? There is no comparison group and no experimental treatment. Researchers will compare paired blood samples collected from opposite sides of the clot in the same participant. Blood collected from a peripheral vein at hospital admission will be used only as a supportive reference for systemic inflammation.\n\nParticipants will:\n\n* Receive standard mechanical thrombectomy and stroke care determined by their treating clinical team.\n* Have small blood samples collected at planned time points, including paired arterial blood samples collected during the thrombectomy procedure.\n* Have clinical and imaging information collected from their medical records and have functional status assessed 90 days after stroke.\n\nThe study will not delay or change standard stroke treatment.",[28,55],[302,303,304,305,306,307,308],"Mechanical Thrombectomy","Anterior Circulation Large Vessel Occlusion","Trans-Thrombus Gradient","Inflammatory Biomarkers","Reperfusion Injury","Modified Rankin Scale","Interleukin-6","2026-08-04",{"date":212,"type":33},{"date":312,"type":22},"2026-08-01",{"date":314,"type":22},"2029-08-01",{"name":316,"class":69},"Zhongshan Hospital Xiamen University",{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":23,"phases":325,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":328,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":4},"100650405","phase-3-study-on-anti-thrombotic-regimens-for-secondary-prevention-in-ischemic-stroke-patients-with-possible-benefit-from-anticoagulation-therapy-100650405","NCT07746882","Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy","Inclusion Criteria:\n\n* Age ≥18 years\n* Ischemic stroke patients with undetermined etiology, within 14 days of onset, with completed etiological assessment\n* At least one of the following:\n\n  1. Cortical or multi-territorial infarct\n  2. Recurrent stroke or stroke on antiplatelet therapy\n  3. Left atrial diameter \\>40 mm\n  4. Left ventricular dysfunction (EF 30-40% or regional wall motion abnormality)\n  5. Atrial premature beats \\>1500\u002F24h\n\nExclusion Criteria:\n\n* Stenosis ≥50% in the responsible vessel or high-risk plaque\n* Identified cardioembolic source\n* PFO with planned closure\n* Malignancy\n* Indication for mandatory anticoagulation\u002Fantiplatelet therapy\n* Active bleeding (intracranial, subarachnoid, gastrointestinal, etc.)\n* History of intracranial hemorrhage\n* Current or recent gastrointestinal ulcer\n* Recent brain or spinal injury\u002Fsurgery\n* Known or suspected vascular malformations or aneurysms\n* Severe renal impairment (CrCl \\\u003C30 ml\u002Fmin)\n* Liver disease with bleeding risk (Child-Pugh B or C)\n* Pregnancy or lactation\n* Other contraindications to anticoagulation",{"count":324,"type":22},680,[25],"To screen ischemic stroke patients likely to benefit from anticoagulation and compare the effectiveness and safety of anticoagulation versus antiplatelet therapy in preventing recurrent ischemic stroke within 3 months.",[249,28],{"date":210,"type":33},{"date":330,"type":22},"2026-08-15",{"date":332,"type":22},"2028-11-30",{"name":334,"class":69},"Second Affiliated Hospital, Zhejiang University, School of Medicine",{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":23,"phases":345,"briefSummary":346,"conditions":347,"keywords":349,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":356,"completionDateStruct":357,"leadSponsor":358,"locationsCount":360},"100650474","phase-3-tenecteplase-or-reteplase-as-bridging-thrombolysis-before-thrombectomy-in-acute-ischemic-cerebrovascular-events-100650474","NCT07748039","Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events","Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events (TRACE-BRIDGE): A Multicenter, Randomized, Open-Label, Three-Arm, Blinded-Endpoint Phase III Trial","TRACE- BRIDGE","Inclusion Criteria:\n\n1. Patients with acute ischemic stroke presenting within 4.5 hours of symptom onset who are eligible for intravenous thrombolytic therapy. A baseline non-contrast CT or MRI is required for screening.\n2. Large vessel occlusion on computed tomographic angiography (CTA) or magnetic resonance angiography (MRA) of the intracranial carotid artery (ICA) or middle cerebral artery (MCA) M1\n3. Age ⩾ 18 years at the time of signing the informed consent form\n4. ASPECTS 6-10\n5. Informed consent from the patients or their legal representative.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage (ICH) identified by CT or MRI\n2. Rapidly improving symptoms at the discretion of the investigator\n3. mRS \\> 2 before stroke onset.\n4. Massive cerebral infarction (infarct size greater than one-third of the blood middle cerebral artery supply area) suggested by CT.\n5. Known contraindication to imaging with contrast agents\n6. Planned adjunct intra-arterial (IA) thrombolysis during or after endovascular treatment (EVT).\n7. Secondary transfer from a primary stroke center\n8. Any terminal illness such that patient would not be expected to survive more than one year\n9. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study\n10. Pregnant women",{"count":344,"type":22},1440,[25],"Acute ischemic stroke caused by large vessel occlusion (LVO) is a major cause of disability, and mechanical thrombectomy (MT) has become the standard treatment for eligible patients. However, the optimal role of intravenous thrombolysis before MT remains uncertain.\n\nThe TRACE-BRIDGE trial is a phase 3, investigator-initiated, multicenter, randomized, open-label trial with blinded outcome assessment (PROBE design) evaluating different bridging thrombolysis strategies before MT. The trial will enroll adults with acute ischemic stroke presenting within 4.5 hours of symptom onset and with imaging-confirmed anterior circulation LVO who are eligible for intravenous thrombolysis and MT.\n\nParticipants will be randomly assigned in a 1:1:1 ratio to receive tenecteplase plus MT, reteplase plus MT, or direct MT alone. The TRACE-BRIDGE trial aims to evaluate the efficacy and safety of bridging thrombolysis with tenecteplase or reteplase before mechanical thrombectomy compared with direct mechanical thrombectomy. The primary outcome is functional independence, defined as a modified Rankin Scale score of 0-2 at 90 days after randomization. If superiority of bridging thrombolysis is demonstrated, the trial will further evaluate whether reteplase is non-inferior to tenecteplase as a bridging thrombolytic strategy.",[28,55,348],"Anterior Circulation Brain Infarction",[59,350,351,352,353],"thrombolysis","thrombectomy","tenecteplase","reteplase","2026-08-03",{"date":210,"type":33},{"date":312,"type":22},{"date":314,"type":22},{"name":359,"class":69},"Yongjun Wang",5,{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":18,"minAge":369,"maxAge":176,"enrollmentInfo":370,"targetDuration":4,"studyType":23,"phases":372,"briefSummary":373,"conditions":374,"keywords":375,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":377,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":4},"100650025","phase-2-a-phase-2a-study-to-evaluate-the-dose-response-safety-tolerability-efficacy-and-population-pharmacokinetics-of-intravenous-nts-521-infusions-in-the-early-recovery-treatment-from-acute-ischemic-stroke-100650025","NCT07742098","A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke","A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Domain Within the ACT-GLOBAL Trial Platform, to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke","ACT-IVATE","Inclusion Criteria:\n\n* Acute ischemic stroke with moderate to severe hemiparesis\n* Functional independence in activities of daily living without requiring nursing care before the index stroke.\n* Consent process by participant or proxy, with reconsent provision.\n* Age ≥ 45 to ≤ 80 years of age (inclusive) on the date of randomization\n* Sufficient attention, comprehension, and cooperation to carry out instructions\n\nExclusion Criteria:\n\n* Pre-existing motor deficit prior to index stroke\n* Posterior circulation ischemic stroke\n* Lacunar stroke\n* Qualifying brain imaging demonstrating intracranial hemorrhage, malignant middle cerebral artery (MCA) infarct with edema, or bilateral\u002Fmultifocal infarcts, clinically significant vascular malformation, brain tumor, or other central nervous system (CNS) pathology\n* Recent major surgery or trauma (\\\u003C30 days)","45 Years",{"count":371,"type":22},140,[132],"This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.",[28],[28,376,248,249],"AIS",{"date":354,"type":33},{"date":379,"type":22},"2026-10-31",{"date":381,"type":22},"2028-12-15",{"name":383,"class":40},"NeuroTrauma Sciences, LLC",{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":391,"enrollmentInfo":392,"targetDuration":4,"studyType":23,"phases":394,"briefSummary":395,"conditions":396,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":399,"completionDateStruct":400,"leadSponsor":402,"locationsCount":97},"100649850","phase-2-the-efficacy-and-safety-of-hrs-4029-in-acute-ischemic-stroke-patients-100649850","NCT07739160","The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients","The Efficacy and Safety of HRS-4029 for the Treatment of Acute Ischemic Stroke: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial","Inclusion Criteria:\n\n1. Fully understand and voluntarily participate in this trial, and sign the informed consent form (the informed consent form can be signed voluntarily by the participant or their legal representative);\n2. Stroke onset within 3 hours prior to screening, and expected to receive study drug administration within 3 hours after stroke onset.\n3. Clinical diagnosis of acute ischemic stroke (AIS).\n4. Modified Rankin Scale (mRS) score ≤1 prior to stroke onset.\n5. National Institutes of Health Stroke Scale (NIHSS) score of 6 to 25 at screening, and the sum of NIHSS score for the upper limb and the lower limb is greater than or equal to 2.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhagic diseases, including but not limited to hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc.;\n2. Severe impairment of consciousness: NIHSS Item 1a (Level of Consciousness) score ≥ 2;\n3. Concurrent other neurological\u002Fpsychiatric disorders (e.g., Parkinsonism, epilepsy, severe cognitive impairment, severe depression, etc.) that render the patient uncooperative or unwilling to cooperate with physical examination, or that may affect the evaluation of outcomes.\n4. Persistent systolic blood pressure ≥ 200 mmHg and\u002For diastolic blood pressure ≥ 110 mmHg following active antihypertensive treatment;\n5. Severe hyperglycemia or hypoglycemia;\n6. Any of the following within 3 months prior to enrollment: acute ST-elevation myocardial infarction , and\u002For acute decompensated heart failure, and\u002For QTc \\> 520 ms, and\u002For hospitalization or unplanned coronary intervention due to acute coronary syndrome, myocardial infarction, or cardiac arrest; or New York Heart Association (NYHA) Class III\u002FIV heart failure; or known ventricular tachycardia;\n7. History of severe hepatic impairment;\n8. History of severe renal insufficiency;\n9. Advanced malignancy or currently undergoing antineoplastic treatment;\n10. Female participants who are pregnant or breastfeeding, or female participants with a positive pregnancy test result at screening;\n11. Participation in another interventional clinical trial involving an investigational drug or medical device (defined as having signed an informed consent form and received the investigational product\u002Fdevice) within 3 months prior to the screening visit;\n12. Terminal illness with an estimated life expectancy of less than 1 year;\n13. Any other condition that, in the opinion of the investigator, renders the participant inappropriate for study participation.","85 Years",{"count":393,"type":22},340,[132],"This trial will evaluate the efficacy and safety of HRS-4029 compared with placebo in participants with acute ischemic stroke (AIS).",[28],"2026-07-28",{"date":116,"type":33},{"date":330,"type":22},{"date":401,"type":22},"2027-07-31",{"name":403,"class":40},"Beijing Suncadia Pharmaceuticals Co., Ltd",{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":411,"targetDuration":413,"studyType":225,"phases":4,"briefSummary":414,"conditions":415,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":424},"100641607","real-world-clinical-evaulation-of-medtronic-neurovascular-products-for-acute-ischemic-stroke-recanova-registry-100641607","NCT07599904","REal-world Clinical evAulation of Medtronic NeurOVascular Products for Acute Ischemic Stroke (RECANOVA Registry)","RECANOVA","Inclusion Criteria:\n\n1. Patient or legally authorized representative (LAR) provides authorization and\u002For consent per institution and geographical requirements.\n2. Participant is treated or intended to be treated with a commercially available Medtronic Neurovascular device\\* during treatment for acute ischemic stroke.\n3. Participant is 18 years of age or older.\n\nExclusion Criteria:\n\n1. Participant who may be unable to complete follow-up within the registry.\n2. Participant of child-bearing potential who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study.\n3. Participant is currently enrolled in, or plans to enroll in, any concurrent drug\u002Fdevice study that may confound the study results based on Principal Investigator's discretion.",{"count":412,"type":22},1500,"90 Days","Post-Market Registry",[28],"2026-07-24",{"date":397,"type":33},{"date":419,"type":33},"2026-07-13",{"date":421,"type":22},"2031-07",{"name":423,"class":40},"Medtronic Neurovascular Clinical Affairs",3,{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":18,"minAge":433,"maxAge":153,"enrollmentInfo":434,"targetDuration":4,"studyType":23,"phases":436,"briefSummary":437,"conditions":438,"keywords":439,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":447,"locationsCount":70},"100596762","hyperbaric-oxygen-after-stroke-thrombectomy-a-multicenter-randomized-trial-on-safety-and-efficacy-100596762","NCT07049692","Hyperbaric Oxygen After Stroke Thrombectomy: A Multicenter Randomized Trial on Safety and Efficacy","Evaluation of the Efficacy and Safety of Hyperbaric Oxygen in Patients After Endovascular Treatment for Acute Ischemic Stroke: A Multicenter, Open-label, Randomized Controlled Clinical Trial","NOTICE-1","Inclusion Criteria:\n\n* 35-75 years\n* The symptoms and signs are consistent with acute anterior circulation ischemic stroke. The immediate postoperative angiographic recanalization grade was ≥ 2b.\n* Neurological deficit score at the time of enrollment: 5 ≤ NIHSS ≤ 15 points\n* Consciousness status (NIHSS 1a-1b items): 0-1 point\n* Pre-stroke functional status (mRS score): 0-1\n* Time from surgery to randomization grouping: ≤ 72 hours\n* Patient or legal representative who signed the informed consent form\n* Preoperative CT angiography or magnetic resonance angiography confirmed large vessel occlusion (internal carotid artery or middle cerebral artery M1 segment) that was consistent with the symptoms and signs; And the area supplied by the middle cerebral artery in the brain is less than 1\u002F3.\n* A lberta S troke P rogram E arly C T S core ≥ 6\n\nExclusion Criteria:\n\n* Subjects with HBO contraindications or intolerance\n* Postprocedural imaging identified either procedure-related subarachnoid hemorrhage or hemorrhagic transformation\n* Based on the medical history, it is suspected that the cerebral embolism is caused by sepsis or infective endocarditis\n* Expected lifespan \\\u003C 90 days\n* Severe heart, liver and kidneys failure\n* Pregnancy\n* Hereditary or acquired bleeding tendency, deficiency of coagulation factors, recent use of oral anticoagulants with an international normalized ratio (INR) \\> 3 or activated partial thromboplastin time (APTT) exceeding the normal value by more than 3 times\n* Baseline platelet count \\\u003C 50×10 9\u002FL\n* Baseline blood glucose is less than 2.78 mmol\u002FL or greater than 22.2 mmol\u002FL.\n* Unstable vital signs (heart rate ≤ 50 beats\u002Fmin or ≥ 120 beats\u002Fmin, oxygen saturation ≤ 90%, respiration ≥ 30 breaths\u002Fmin or ≤ 10 breaths\u002Fmin);\n* Hypertension that cannot be controlled by medication: Systolic blood pressure ≥ 160 mmHg, or diastolic blood pressure ≥ 100 mmHg;\n* Suspected of having acute myocardial infarction;\n* Currently involving in the research of other projects related to drugs or medical devices.\n* CT or MRI scans revealed intracranial tumors (except for cerebellar meningiomas) and intracranial arteriovenous malformations.\n* Based on the medical history and CT or MRI findings, a diagnosis of internal carotid artery dissection or aortic dissection is suspected;\n* Based on the medical history and CT or MRI findings, cerebral vasculitis is suspected.\n* Based on the clinical evidence of multiple vascular regions being occluded (either in the bilateral anterior circulation or anterior\u002Fposterior circulation) or bilateral infarction or multi-region infarction as detected by CT angiography or magnetic resonance angiography;\n* CT or magnetic resonance imaging shows a significant midline shift effect (\\> 0.5 cm);\n* CT angiography or magnetic resonance angiography confirmed the presence of cerebral vasculitis or cerebral vasculitis syndrome;","35 Years",{"count":435,"type":22},424,[109],"1. The goal of this clinical trial is to evaluate the efficacy and safety of hyperbaric oxygen (HBO)in stroke patients after endovascular treatment\n2. The main questions it aims to answer is:\n\n   Whether HBO can improve the prognosis of ischemic stroke patients after endovascular treatment?\n3. Participants will:\n\nreceive HBO (1.6 Atmosphere Absolute，1.6ATA)，Once a day, for 1 hour each time, for 5 days a week (it can be non-consecutive days), the total course of treatment is 10 times.\n\nundergo three scheduled face to face or telephone follow-up assessments during the 12-month period following HBO.",[28],[440,59,441],"HBO","endovascular treatment","2026-07-23",{"date":416,"type":33},{"date":445,"type":33},"2026-07-22",{"date":66,"type":22},{"name":448,"class":69},"Beijing Chao Yang Hospital",{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":456,"enrollmentInfo":457,"targetDuration":4,"studyType":23,"phases":459,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":424},"100619672","randomized-clinical-trial-of-endovascular-therapy-for-acute-ischemic-stroke-with-occlusion-of-the-m2-segment-of-middle-cerebral-artery-100619672","NCT07347665","Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle Cerebral Artery","Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle Cerebral Artery (the Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism-M2 Occlusion Trial: RESCUE-M2O Trial)","Inclusion Criteria:\n\n1. Acute cerebral infarction\n2. Aged 18-84 years\n3. NIHSS score at admission ≥ 8\n4. Prestroke mRS scores of 0-1 (able to carry out all usual activities)\n5. Occlusion of the M2 segment of MCA on digital subtraction angiography\n6. ASPECTS ≥ 8 or DWI-ASPECTS ≥ 8\n7. Ineligible or failed intravenous tPA (no recanalization within 30 min after injection)\n8. Randomization can be completed within 24 h from the last known well time\n9. EVT can be initiated within 30 min from randomization.\n10. The patient or their legally authorized representative has signed the informed consent form.\n\nExclusion Criteria:\n\n1. Occlusion of the anterior temporal artery, duplicate M1, or accessory M1\n2. Occlusion of multiple major intracranial arteries\n3. Difficulty in endovascular access due to tortuous vascular anatomy\n4. Significant mass effect with midline shift on CT (or MRI)\n5. Known allergy (more severe than skin rash) to contrast agents\n6. Evidence of acute intracranial hemorrhage on CT (or MRI)\n7. Pregnant or potentially pregnant\n8. Clinical evidence of chronic occlusion\n9. High risk of hemorrhage (platelet \\\u003C 40,000\u002Ful, APTT \\> 50 sec or PT-INR \\> 3.0)\n10. Participating in any other therapeutic investigational trial\n11. Judgment of the investigator to be non-compliant or uncooperative during the study","84 Years",{"count":458,"type":22},200,[109],"RESCUE-M2O trial is a prospective, open label, blinded endpoint (PROBE), two-arm, randomized, controlled, post-market study to assess the efficacy and safety of endovascular therapy for acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery.",[462,28,228],"Endovascular Therapy","2026-07-15",{"date":465,"type":33},"2026-07-17",{"date":467,"type":33},"2025-12-01",{"date":469,"type":22},"2030-03-31",{"name":471,"class":69},"Hyogo Medical University",{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":225,"phases":4,"briefSummary":481,"conditions":482,"keywords":486,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":500},"100616006","efficacy-and-safety-of-intravenous-thrombolysis-in-branch-atheromatous-disease-100616006","NCT07299994","Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease","Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease - a Retrospective Data Analysis","Inclusion Criteria:\n\n* aged over 18 years, with acute ischemic stroke and symptom onset no more than 24 hours before admission, who were treated in one of the stroke units of the participating institutions.\n* All enrolled patients must have undergone a cerebral MRI for inclusion:\n\n  1. DWI lesion: single isolated deep subcortical stroke AND\n  2. The affected vessel involves the LSA, PPA, or ACHA, and the infarct lesion on DWI conforms to one of the following characteristics (A, B, OR C):\n\nA. LSA: \"Comma-like\" infarct lesions with \"fan-shaped\" extension from bottom to top in the coronary position OR ≥ 3 layers (layer thickness 5 mm) on axial DWI.\n\nB. PPA: Infarct lesion extending from the deep pons to the ventral pons on axial DWI.\n\nC. ACHA: Infarct within the anterior choroidal artery territory.\n\nExclusion Criteria:\n\n* Typical recent small subcortical infarction (RSSI) (oval, \\\u003C20mm in all axes)\n* ≥ 50% stenosis on the parent artery (i.e., BA, MCA, or ICA)\n* Stroke due to other clearly identified causes or possible cardioembolic etiology.",{"count":480,"type":22},462,"Rationale and Relevance:\n\nBranch Atheromatous Disease (BAD) describes an atherosclerotic occlusion of one of the deep penetrating cerebral arteries, including the lenticulostriate artery (LSA), paramedian pontine artery (PPA), and anterior choroidal artery (ACHA). BAD is frequently associated with early neurological deterioration (END), particularly progressive motor deficits that contribute to increased disability. Despite its clinical relevance, BAD remains underrepresented in major radiomorphological classification systems such as TOAST, which has led to limited evidence and unclear treatment strategies. Previous studies suggest that the efficacy of intravenous thrombolysis (IVT) may be reduced in BAD compared to other stroke etiologies.\n\nObjectives:\n\nThe primary objective of this study is to evaluate the efficacy and safety of IVT compared with single antiplatelet therapy (SAPT) and dual antiplatelet therapy (DAPT) in patients with BAD-related stroke. A secondary objective is to examine the impact of acute-phase blood pressure fluctuations on END and functional neurological outcomes.\n\nDesign and Methods:\n\nThis international multicenter study will be conducted retrospectively according to the STROBE guidelines. Eligible patients include those with BAD-related stroke treated at one of the participating centers between 2010 and 2025. Inclusion criteria comprise characteristic diffusion-weighted MRI patterns in predefined vascular territories (LSA, PPA, ACHA) and a symptom onset ≤24 hours before admission. Patients with typical lacunar infarcts or with other identified stroke etiologies will be excluded.\n\nEndpoints:\n\nPrimary endpoints include functional outcome at three months, defined as a favorable outcome with a modified Rankin Scale score of 0-1; occurrence of END, defined as a ≥4-point worsening on the NIHSS within 24-48 hours; and symptomatic intracerebral hemorrhage. Collected data include clinical, imaging, and therapeutic variables, as well as blood pressure trajectories and pre-stroke treatments (as detailed in the study protocol).\n\nStatistical Analysis:\n\nAnalyses will be performed using SPSS and R. Descriptive statistics, univariate analyses, and multivariable models (IPTW and Poisson regression) will be applied. Results will be reported as adjusted relative risks with 95% confidence intervals.\n\nSignificance:\n\nThis study will provide the first comprehensive evaluation of IVT versus SAPT\u002FDAPT in BAD-related stroke, and will investigate the clinical impact of blood pressure changes in this specific stroke subtype. The findings aim to support evidence-based treatment recommendations for a currently underrecognized and poorly understood stroke etiology.",[249,483,484,485,28],"Thrombolysis","DAPT(Dual Antiplatelet Therapy)","SAPT(Single Antiplatelet Therapy)",[487,488,483,489,490],"Acute ischemic Stroke","Branch Atheromatous Disease","DAPT","SAPT","2026-07-14",{"date":493,"type":33},"2026-07-16",{"date":495,"type":33},"2026-01-01",{"date":497,"type":22},"2026-12-31",{"name":499,"class":69},"Sigmund Freud PrivatUniversitat",8,{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":176,"enrollmentInfo":508,"targetDuration":4,"studyType":23,"phases":510,"briefSummary":511,"conditions":512,"keywords":513,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":517,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":70},"100596581","urokinase-for-thrombolysis-in-acute-ischemic-stroke-100596581","NCT07047326","Urokinase for Thrombolysis in Acute Ischemic Stroke","A Dose-Escalation Safety Study of Urokinase for Thrombolysis in Patients With Acute Ischemic Stroke","Inclusion Criteria:\n\n1. Age 18-80 years, male or female.\n2. Clinical diagnosis as ischemic stroke (the diagnosis following the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023).\n3. Time from onset to treatment \\\u003C6h; the time of symptom onset is defined as \"the last time point at which the patient appears normal\", and the symptoms of stroke persist for at least 30 minutes and show no significant improvement before treatment.\n4. NIHSS ≥1 at baseline.\n5. Subjects or their guardians voluntarily sign the informed consent.\n\nExclusion Criteria:\n\n1. Head CT or MRI shows a large infarction (infarcted area \\>1\u002F3 of the middle cerebral artery).\n2. Unknown time of stroke onset.\n3. Pre-stroke mRS score ≥2.\n4. NIHSS score 1A ≥2.\n5. Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural\u002Fextradural hematoma, etc.).\n6. A history of intracranial hemorrhage.\n7. Propensity for acute bleeding, including platelet count \\\u003C100 × 10⁹\u002FL or otherwise.\n8. Having received heparin treatment within 24 h.\n9. On oral anticoagulants (e.g., warfarin) with INR \\>1.7 or PT \\>15s.\n10. Patients with planned or prior endovascular therapy.\n11. A history of severe head trauma or stroke within 3 months.\n12. Intracranial tumors, large intracranial aneurysms.\n13. A history of intracranial or spinal surgery within 3 months.\n14. A history of major surgery within 2 weeks.\n15. Severe liver impairment (e.g., liver failure, cirrhosis, portal hypertension \\[esophageal varices\\], active hepatitis).\n16. A history of gastrointestinal or urinary tract hemorrhage within 3 weeks.\n17. Active visceral bleeding.\n18. Aortic dissection found.\n19. A history of arterial puncture at sites difficult for compression hemostasis within 1 week.\n20. Life expectancy \\\u003C1 year due to comorbid conditions.\n21. Uncontrollable hypertension upon active antihypertensive treatment: systolic blood pressure ≥180 mm Hg, or diastolic blood pressure ≥100 mm Hg on ≥3 repeated measurements at 10-minute intervals.\n22. Blood glucose \\\u003C2.8 mmol\u002FL or \\>22.2 mmol\u002FL.\n23. Subjects who are unable or unwilling to cooperate due to hemiplegia after epileptic seizure or other neurological\u002Fpsychiatric disorders.\n24. Known to be allergic to urokinase.\n25. Bacterial endocarditis, pericarditis, or acute pancreatitis.\n26. Participation in other clinical trials within 30 days before screening.\n27. Pregnancy, lactating women, or subjects who do not agree to use effective contraception during the trial.\n28. Other conditions deemed by the investigator to impair adherence or pose risks to participants.",{"count":509,"type":22},24,[109],"According to the Chinese Guidelines for the Diagnosis and Treatment of Ischemic Stroke, intravenous thrombolysis with urokinase, administered at doses of 1-1.5 million IU within 6 hours of symptom onset, has been shown to be both safe and effective for patients with acute ischemic stroke. Compared to alteplase, urokinase offers considerable cost advantages while maintaining comparable therapeutic efficacy. However, current dosing protocols in clinical practice largely rely on the empirical judgment of physicians rather than evidence-based standardization. Therefore, the development of a weight-adjusted dosing regimen for urokinase is of significant clinical importance in optimizing treatment outcomes and ensuring patient safety. The purpose of this study is to determine the maximum tolerated dose of urokinase thrombolytic treatment in patients with acute ischemic stroke and to develop an optimal weight-adjusted dosing regimen.",[28],[514,515,516],"Acute ischemic stroke","Intravenous thrombolysis","Urokinase",{"date":491,"type":33},{"date":519,"type":33},"2025-10-01",{"date":521,"type":22},"2027-01-02",{"name":287,"class":69},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":225,"phases":4,"briefSummary":531,"conditions":532,"keywords":537,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":550,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":97},"100593973","transcranial-doppler-evaluation-after-endovascular-thrombectomy-for-acute-ischemic-stroke-precise-tcd-100593973","NCT07013396","Transcranial Doppler Evaluation After Endovascular Thrombectomy for Acute Ischemic Stroke (PRECISE-TCD)","A Prospective Evaluation of Clinical Outcomes in Acute Ischemic Stroke After Endovascular Treatment Using Transcranial Doppler (PRECISE-TCD)","Inclusion Criteria:\n\n* Anterior circulation large vessel occlusion, including ACA, MCA, or ICA stroke, treated with endovascular thrombectomy, including tandem occlusions\n* Age ≥ 18 years\n* Ability to detect an adequate acoustic window via TCD.\n\nExclusion Criteria:\n\n* Inadequate acoustic windows defined as lack of bilateral MCA signal at standard depths.\n* Pregnancy\n* Incarceration",{"count":178,"type":22},"Endovascular thrombectomy (EVT) improves outcomes in acute ischemic stroke caused by large vessel occlusion. Despite successful recanalization, early neurological deterioration (END) remains frequent and is associated with poor outcomes. Transcranial Doppler (TCD) provides noninvasive, real-time assessment of cerebral blood flow velocities and may identify hemodynamic patterns associated with deterioration after EVT. PRECISE-TCD is a prospective, single-center observational study enrolling 180-300 patients undergoing EVT for anterior circulation large vessel occlusion at a tertiary academic medical center. Serial TCD examinations are performed immediately after EVT, daily for 72 hours, and as close as possible to early neurological deterioration events or clinically indicated head CT within 72 hours. The primary outcome is the association between TCD-derived hemodynamic parameters and END within 72 hours. Secondary outcomes include NIHSS at 24 hours and discharge, discharge disposition, and modified Rankin Scale at 90 days.",[533,534,28,535,536],"Anterior Cerebral Artery Syndrome","Anterior Cerebral Artery Stroke","Cardioembolic Stroke","Vasogenic Cerebral Edema",[538,539,55,540,541,542,543,544,545,546,547,548,549,307],"systolic blood pressure","Transcranial Doppler","mean flow velocity","early neurological deterioration","cerebral hemodynamics","endovascular thrombectomy","cerebral autoregulation","blood pressure management","collateral circulation","pulsatility index","peak systolic velocity","end-diastolic velocity",{"date":493,"type":33},{"date":552,"type":22},"2026-08",{"date":554,"type":22},"2029-08",{"name":556,"class":69},"Virginia Commonwealth University",{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":23,"phases":566,"briefSummary":567,"conditions":568,"keywords":569,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":97},"100643707","rise-stroke-mobility-study-100643707","NCT07638462","RIsE Stroke Mobility Study","RIsEStroke (Recovery Insights Into Early Mobility Post Stroke)","RIsE","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Hospitalized patients with acute ischemic stroke\n* Initial National Institutes of Health Stroke Scale (NIHSS) score of 10 or greater\n* Baseline modified Rankin Scale (mRS) score of 0-2\n* Current modified Rankin Scale (mRS) score of 3-5\n\nExclusion Criteria:\n\n* Current or expected End-of-life discussions\n* Current plans for surgical intervention\n* Patients with pre-mRS of 3-5\n* Patients with orthopedic, musculoskeletal, integumentary injury that would prevent safe weight bearing, mobility or equipment use\n* Uncontrolled cardiorespiratory dysfunction or disease\n* Active\u002Funcontrolled seizures\n* Isolation status that would prevent mobility outside of the room\n* Weight that exceeds the safe limits of mobility equipment",{"count":298,"type":22},[109],"This study is designed to better understand how patients with severe stroke move during their hospital stay. It will track their activity using a small wearable device (activPAL) along with standard mobility information already collected in clinical care. The goal is to learn what typical movement patterns look like early after a stroke and how well patients meet mobility goals while in the hospital. What is learned from this study may allow determination of how treatment for stroke patients may be improved to improve patient long-term mobility.",[28],[570,571,572],"stroke","mobility","advanced therapy","2026-07-09",{"date":575,"type":33},"2026-07-10",{"date":577,"type":33},"2026-07-08",{"date":579,"type":22},"2027-04",{"name":581,"class":69},"Wake Forest University Health Sciences",{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":176,"enrollmentInfo":590,"targetDuration":413,"studyType":225,"phases":4,"briefSummary":592,"conditions":593,"keywords":595,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":607,"completionDateStruct":608,"leadSponsor":610,"locationsCount":612},"100646260","early-identification-and-diagnosis-of-bad-related-stroke-100646260","NCT07693816","Early Identification and Diagnosis of BAD-related Stroke","Establishment and Validation of a Novel Intelligent Diagnostic Model for BAD-related Stroke Based on the Fusion of Multi-source Clinical Image Information and Its Promotion","SMART-BAD","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Diagnosis of acute ischemic stroke.\n* Time from symptom onset to enrollment ≤ 1 week; if the onset time is unknown, time from last known well to enrollment ≤ 1 week.\n* Availability of required baseline clinical and neuroimaging assessments according to the study protocol.\n* Written informed consent provided by the participant or legally authorized representative.\n\nParticipants will be classified into the BAD-related stroke cohort if they meet all predefined BAD-related stroke diagnostic criteria, including:\n\n* A single isolated deep subcortical infarct on diffusion-weighted imaging.\n* The presumed culprit perforating artery is the lenticulostriate artery or the paramedian pontine artery.\n* For lenticulostriate artery territory infarction: a comma-shaped lesion extending from inferior to superior direction on coronal DWI or involvement of ≥3 axial DWI slices with 5-7 mm slice thickness.\n* For paramedian pontine artery territory infarction: a lesion extending from the deep pons to the ventral surface of the pons on axial DWI.\n* No ≥50% stenosis of the corresponding parent artery, confirmed by MRA, CTA, or DSA.\n\nParticipants with acute ischemic stroke who do not meet BAD-related stroke criteria will be classified into the non-BAD acute ischemic stroke cohort.\n\nExclusion Criteria:\n\nGeneral exclusion criteria for all participants:\n\n* Intracranial hemorrhage, vascular malformation, aneurysm, brain abscess, malignant intracranial mass, or other non-ischemic intracranial lesion on baseline CT, MRI, MRA, CTA, or DSA.\n* Pre-stroke modified Rankin Scale score ≥2.\n* Life expectancy ≤6 months.\n* Unable to tolerate MRI examination.\n* Pregnancy or breastfeeding.\n* Participation in another clinical study within 3 months before informed consent or current participation in another clinical study that may interfere with this study.\n\nAdditional criteria that preclude classification as BAD-related stroke:\n\n* Ipsilateral extracranial tandem artery stenosis ≥50%.\n* Definite cardioembolic source, including atrial fibrillation, myocardial infarction, clinically significant valvular heart disease, dilated cardiomyopathy, infective endocarditis, atrioventricular conduction disease, or heart rate \\\u003C50 beats\u002Fmin as defined in the protocol.\n* Receipt of or planned acute-phase endovascular treatment after stroke onset.\n* Stroke due to other determined causes, such as moyamoya disease, arterial dissection, or vasculitis.",{"count":591,"type":22},1602,"Branch atheromatous disease (BAD)-related stroke is an important subtype of acute ischemic stroke involving penetrating arteries and is associated with early neurological deterioration. Early recognition and standardized diagnosis remain challenging in routine clinical practice because clinical symptoms are often non-specific and the diagnosis requires integrated clinical and imaging assessment.\n\nThis multicenter prospective observational study will collect demographic, clinical, laboratory, electrocardiographic, ultrasound, and multimodal neuroimaging data from adults with acute ischemic stroke within 1 week of symptom onset. Participants will receive routine clinical care determined by their treating physicians; no treatment or management strategy will be assigned by the study protocol. An independent central clinical-imaging adjudication committee will classify participants as BAD-related stroke or non-BAD acute ischemic stroke according to predefined diagnostic criteria. The study aims to develop and externally validate artificial intelligence-assisted screening and diagnostic models for BAD-related stroke and to evaluate their discrimination, calibration, and potential clinical utility.",[488,28,594],"Cerebral Infarction",[596,514,597,598,599,600,601,602,603,604],"Branch atheromatous disease","Artificial intelligence","Machine learning","Deep learning","Diagnostic model","Multimodal imaging","Magnetic resonance imaging","Lenticulostriate artery","Paramedian pontine artery","2026-07-05",{"date":573,"type":33},{"date":463,"type":22},{"date":609,"type":22},"2028-12-31",{"name":611,"class":69},"Peking Union Medical College Hospital",11,{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":391,"enrollmentInfo":621,"targetDuration":4,"studyType":23,"phases":623,"briefSummary":624,"conditions":625,"keywords":626,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":636},"100601856","medical-management-with-endovascular-thrombectomy-versus-medical-management-alone-in-patients-presenting-beyond-24-hours-of-last-known-well-100601856","NCT07115940","Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours of Last Known Well","Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours of Last Known Well - SELECT LATE Trial","SELECT LATE","Inclusion Criteria:\n\nGeneral Inclusion Criteria:\n\n* Adults (18-85\\* years) with the final diagnosis of an acute ischemic stroke$\n* NIHSS ≥ 6\n* Time from last-known-well to randomization \\>24 - 72 hours\n* Pre-stroke modified Rankin Scale score of 0-1\n* Eligible for thrombectomy and medical management\n* Signed Informed Consent obtained\n* Subject willing to comply with the protocol follow-up requirements\n* Anticipated life expectancy of at least 3 months \\*Inclusive of both 18 and 85 years of age (i.e. up to 86th birthdate). $Subacute presentation - In-hospital stroke admissions with fluctuating clinical symptoms for patients who presented to EVT centers within 24 hours of when they were last known well will not be eligible for the trial.\n\nGeneral Exclusion Criteria\n\n* Current participation in another investigational interventional drug or device study.\n* Baseline Platelet count \\\u003C100,000\u002Fμl\n\nImaging Inclusion Criteria\n\n* Proven large vessel occlusion in ICA or MCA-M1 occlusion (carotid occlusions can be cervical or intracranial, with or without tandem MCA lesions), as determined by MR Angiography (MRA) or CT Angiography (CTA)\n* CT ASPECTS 3-10\n* CT Perfusion ischemic core (rCBF \\\u003C30%)# volume ≤150 ml OR MR Diffusion ischemic core (ADC \\\u003C620x10-6 mm2\u002Fs)# volume ≤150ml #If the perfusion software at enrollment center uses another threshold\u002Fmeasure to define ischemic core, please use that measure to assess ischemic core criteria.\n\nImaging Exclusion Criteria\n\n* Evidence of intracranial tumor (except small meningioma \\\u003C3cm without signs of edema or inflammation), acute intracranial hemorrhage, or arteriovenous malformation\n* Significant mass effect, defined as midline shift (\\>3mm) using foramen of monroe (anterior margin of third ventricle) as the marker for midline instead of septum pellucidum AND\u002FOR Effacement of sulci in contralateral hemisphere\n* Evidence of internal carotid artery dissection that is flow limiting or aortic dissection\n* Intracranial stent implanted in the same vascular territory that precludes the safe deployment\u002Fremoval of the neurothrombectomy device\n* Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA\u002FMRA (e.g., bilateral MCA occlusions, or an MCA and a basilar artery occlusion).\n* Any signs of established infarct, demarcating hypodensity and area of cerebral edema on non-contrast CT\n* CT ASPECTS 0-2\n* CT Perfusion ischemic core (rCBF \\\u003C30%)# volume \\>150 ml OR MR Diffusion ischemic core (ADC \\\u003C620x10-6 mm2\u002Fs)# volume \\>150ml #If the perfusion software at enrollment center uses another threshold\u002Fmeasure to define ischemic core, please use that measure to assess ischemic core criteria.",{"count":622,"type":22},408,[109],"SELECT LATE trial aims to evaluate if addition of endovascular thrombectomy to medical management in patients presenting with acute ischemic stroke and a proximal large vessel occlusion in the anterior circulation between 24 and 72 hours of stroke onset results in achieving better functional outcomes (measured using modified Rankin Scale Scores) at 90-day follow-up (± 15 days).",[28],[183,302],"2026-07-01",{"date":629,"type":33},"2026-07-06",{"date":631,"type":33},"2026-04-13",{"date":633,"type":22},"2029-12-01",{"name":635,"class":69},"Amrou Sarraj",6]